SEC Form 4 · accession 0001209191-16-149950
ADURO BIOTECH, INC. · ADRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas W. Dubensky
Officer — Chief Scientific Officer
Period of report
Nov 10, 2016
Accepted (ET)
Nov 14, 2016 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001435049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 10, 2016 | M | 21,062 | $1.45 | A | 60,962 | D | |
| Common Stock | Nov 10, 2016 | M | 3,938 | $0.52 | A | 64,900 | D | |
| Common StockF2 | Nov 10, 2016 | S | 25,000 | $14.7763 | D | 39,900 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $1.45 | Nov 10, 2016 | M | 21,062 | D | — | Jan 9, 2025 | Common Stock | 21,062 | 194,083 | D |
| Employee Stock Option (right to buy)F4 | $0.52 | Nov 10, 2016 | M | 3,938 | D | — | Oct 23, 2021 | Common Stock | 3,938 | 72,684 | D |
Explanation of responses
- F1The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2016.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.20 to $15.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015.
- F4The shares subject to the Option were fully vested as of December 31, 2015.